Maputo — 3,413 patients across Mozambique are undertaking the new tuberculosis preventive therapy, coupling strong doses of isoniazid (H) and rifapentine (P), to prevent simple and non-contagious cases from worsening and increasing the number of infected people.
The new therapy, launched in March by the Mozambican government in partnership with the IMPAACT4TB consortium, is a four year project which introduces a new approach not only to deal with latent infection but also to fight abandonment of treatment and thus increase efficacy levels.
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article